Johnson & Johnson's press release — JNJ's reaction is being measured
JNJ's realized reaction is still being measured.
· PR Newswire · Press release · Realized reaction, point-in-time, zero look-ahead.
RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) combination demonstrates 77% overall response rate in first-line treatment of patients with advanced head and neck cancer
Via PR Newswire
Reaction is being measured.
This event is recent. News Quantified labels the realized price reaction once the trading sessions after the news complete — point-in-time, with zero look-ahead. The measured move will appear here, and below in JNJ’s reaction history.
Where this JNJ event came from, and what the tape did with it.
Johnson & Johnson issued a press release, carried via PR Newswire, on Oct 25, 2026. It was one of 2 Johnson & Johnson headlines News Quantified labeled that day, so its measurement window overlaps with the others on a shared tape. The same session also carried Johnson & Johnson's "Johnson & Johnson reports 75% tumor response rate in advanced…", each measured on its own clock.
Against the price at the news timestamp, JNJ's reaction is still being measured. Because several releases shared that day, their measurement windows overlap and no single headline cleanly owns the move.
How this compares to JNJ’s usual reaction.
Across 2,000+ labeled events, JNJ’s median 30-minute reaction to all news is +0.06% (56% up); by the close it is +0.06%.
| Middle 50% of JNJ reactions | -0.26% to +0.39% |
|---|---|
| Median reaction (30-min) | +0.06% |
| Measured reactions | 2,000+ |
Half of all Johnson & Johnson news events land between -0.26% and +0.39% at 30 minutes; this one is a single draw from that distribution.
You just saw one reaction. There are 26M+ more.
See the full JNJ reaction history →Email me when JNJ moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to JNJ's baseline. Nothing else.
How comparable JNJ events have landed.
Across 5 other recent Johnson & Johnson press release events, the median close-day reaction was +0.62%. Each is measured the same way, from its own news timestamp.
8 more JNJ events, each measured the same way.
Recent JNJ events, each with its measured reaction8
That same day, across the market1
Same measurement, same clock, different names — each headline measured from its own news timestamp, point-in-time.
Peer tickers, measured the same way4
Every US ticker is measured the same way, from its own news timestamp. Browse all tickers →
JNJ carried 1 other record that day.
Each was measured the same way, from its own timestamp.
| Record | Event | 5-min | To close |
|---|---|---|---|
| Johnson & Johnson reports 75% tumor response rate in advanced prostate cancer with JNJ-6143, a first-in-class RIPTAC™ molecule | Press release | — | — |
How the numbers are made.
How was JNJ's 5-minute reaction measured?
From the news timestamp, not the trading day: News Quantified takes the last trade before this press release as the base price and measures the move five minutes of trading later — point-in-time, zero look-ahead. The same clock produced the to-close figure.
What is Johnson & Johnson's median reaction, and how does this event compare?
Johnson & Johnson's median is drawn from 2,000+ labeled events; at 30 minutes it sits at +0.06%, and +0.06% by the close. This event's move is one draw from that distribution — ordinary or outlier, the chart's median ticks show which.
2 Johnson & Johnson headlines shared Oct 25, 2026. Whose reaction is this?
Each of the 2 same-day Johnson & Johnson events is measured from its own timestamp, but their windows overlap on one tape, so we show the cluster rather than pretending a single headline owns the move.
Does a measured reaction predict Johnson & Johnson's next reaction?
No. a measured reaction is a realized fact about Oct 25, 2026, not a forecast. Past reactions describe a distribution; they say nothing certain about any future move.
How to cite this reaction.
News Quantified. "RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) combination demonstrates 77% overall response rate in first-line treatment of patients with advanced head and neck cancer." JNJ realized price reaction, Oct 25, 2026. Retrieved from https://newsquantified.com/tickers/jnj/news/rybrevant-faspro-amivantamab-hyaluronidase-lpuj-combination-2026-10-25
Canonical URL: https://newsquantified.com/tickers/jnj/news/rybrevant-faspro-amivantamab-hyaluronidase-lpuj-combination-2026-10-25
Query this dataset via the API & MCP →